Detalles de la búsqueda
1.
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
J Neurovirol;
25(1): 22-31, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30298202
2.
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study.
AIDS Res Ther;
16(1): 1, 2019 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30651100
3.
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
BMC Infect Dis;
17(1): 256, 2017 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28399804
4.
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
HIV Clin Trials;
13(5): 233-44, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23134624
5.
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
AIDS;
35(8): 1201-1208, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33710017
6.
Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
AIDS Patient Care STDS;
35(11): 419-427, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34609897
7.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient;
14(6): 849-862, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34056699
8.
Estimated glomerular filtration rates through 144âweeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
HIV Clin Trials;
16(4): 125-9, 2015 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26133089
9.
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV Clin Trials;
11(2): 69-79, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20542844
10.
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).
AIDS Res Ther;
6: 3, 2009 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-19358725
11.
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Pharmacotherapy;
39(1): 40-54, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30414209
12.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
PLoS One;
14(11): e0225199, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31725787
13.
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Pharmacotherapy;
28(3): 314-22, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18294111
14.
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
AIDS Res Hum Retroviruses;
34(8): 672-679, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29732898
15.
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
HIV AIDS (Auckl);
9: 51-61, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424561
16.
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
HIV Clin Trials;
7(5): 229-36, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17162316
17.
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
Pharmacotherapy;
24(3): 307-12, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15040643
18.
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Pharmacotherapy;
23(11): 1432-40, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14620390
19.
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.
PLoS One;
9(2): e89611, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24586911
20.
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
PLoS One;
9(5): e96187, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24825167